Renal Biobank and TARGET-KD
Summary
The TARGET-KD program (The Application of Renal Genomics to Enhance the Treatment of Kidney Disease) is seeking to recruit subjects who are scheduled to undergo a kidney biopsy in the near future who are willing to donate a one-time urine and blood sample to the kidney disease biobank at the University of Calgary. Samples will be de-identified and used in future studies in order to discover and validate disease-classifying molecular and genetic indicators that may exist in the blood and urine. These discoveries could lead to the development of simple urine or blood-based diagnostic tests rather than requiring an invasive kidney biopsy to diagnose patients and treat them appropriately. We are also actively recruiting healthy volunteers without kidney disease to donate urine and blood samples on a one-time basis to be used as controls for comparison studies.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Accepts healthy participants: Yes
Inclusion criteria:
Kidney disease patients:
a. Undergoing kidney biopsy procedure in Calgary
b. Patient or guardian (for patients <18 years of age) able to provide consent, medical information
Healthy Volunteers:
a. > 18 years of age
b. Willing to complete a 10-15 minute study visit at the University of Calgary
c. Willing to disclose smoking status, prior medical complications, medications
d. Can provide Alberta Provincial health card number
Exclusion criteria:
Kidney disease patients:
a. Unable to consent, fully disclose medical information
Healthy Volunteers:
a. < 18 years of age
b. Any systemic or chronic disease history
c. Unable to fully disclose smoking status, prior medical complications, medications
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
If you would like to learn more, please visit www.target-kd.com or contact Graciela Andonegui at 403-210-7097 or andonegu@ucalgary.ca
Principal investigator:
Daniel Abraham Muruve
Clinical trial:
No
REB-ID:
REB17-0639